Obesity Discussion Forums - View Single Post - Predix moves obesity and memory compound into phase 1

Obesity Discussion · 06-10-06, 02:01 AM

Predix moves obesity and memory compound into phase I8th June 2006
By Helen Marshall
Predix Pharmaceuticals has initiated a phase I clinical trial in healthy volunteers to study the safety, tolerability, and pharmacokinetics of PRX-07034, which is being developed for the treatment of obesity and cognitive impairment.
PRX-07034 is the fourth novel drug candidate from Preix' drug discovery platform to progress into human clinical trials. It is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor (GPCR) known as 5-HT6. PRX-07034 has shown cognitive-enhancing properties in preclinical animal models of memory impairment, as well as significant reductions of both food intake and body weight in several preclinical animal models of obesity.

AdvertisementIndications are that the human 5-HT6 receptor is found mainly in the central nervous system, with little or no expression in peripheral tissues, which may result in selectivity in drug targeting with fewer side effects.

The phase I trial will evaluate PRX-07034 in 18 healthy adults. Predix anticipates being able to announce results from the trial later this year.

Article

06-10-06, 02:01 AM	#1 (permalink)
Obesity Discussion Administrator Join Date: Jan 2005 Location: Phoenix, AZ Posts: 7,795 Weight Statistics 8/1/2006 Start Date: 185 lb Start Weight: 152 lb Current Weight: 155 lb Goal Weight: -33 lb Weight Loss: 5/1/2007 Goal Date:	Predix moves obesity and memory compound into phase 1 Predix moves obesity and memory compound into phase I8th June 2006 By Helen Marshall Predix Pharmaceuticals has initiated a phase I clinical trial in healthy volunteers to study the safety, tolerability, and pharmacokinetics of PRX-07034, which is being developed for the treatment of obesity and cognitive impairment. PRX-07034 is the fourth novel drug candidate from Preix' drug discovery platform to progress into human clinical trials. It is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor (GPCR) known as 5-HT6. PRX-07034 has shown cognitive-enhancing properties in preclinical animal models of memory impairment, as well as significant reductions of both food intake and body weight in several preclinical animal models of obesity. AdvertisementIndications are that the human 5-HT6 receptor is found mainly in the central nervous system, with little or no expression in peripheral tissues, which may result in selectivity in drug targeting with fewer side effects. The phase I trial will evaluate PRX-07034 in 18 healthy adults. Predix anticipates being able to announce results from the trial later this year. Article __________________